State Street SPDR S&P Pharmaceuticals ETF
XPH
70 hedge funds and large institutions have $154M invested in State Street SPDR S&P Pharmaceuticals ETF in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 28 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.53% less ownership
Funds ownership: 51.24% → 45.71% (-5.5%)
7% less funds holding
Funds holding: 75 → 70 (-5)
15% less capital invested
Capital invested by funds: $182M → $154M (-$28M)
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
54% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 28
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $529K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGGDR
JGP Global Gestao de Recursos
Rio De Janeiro,
Brazil
|
+$6.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$2.53M |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$914K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$721K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$619K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
Bell Bank
Fargo,
North Dakota
|
-$18.1M |
| 2 |
Morgan Stanley
New York
|
-$9.86M |
| 3 |
AL
Arnhold LLC
New York
|
-$3.54M |
| 4 |
Jane Street
New York
|
-$1.86M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJFSA
76
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$237K | -5,665 | Closed |
|
|
SWP
77
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$99K | -2,365 | Closed |
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$24K | -564 | Closed |
|
|
SFSIG
79
San Francisco Sentry Investment Group
San Francisco,
California
| – | -$5K | -114 | Closed |
|
|
CG
80
Cutler Group
San Francisco,
California
| – | -$4.2K | -100 | Closed |
|
|
SBL
81
Sargent Bickham Lagudis
Boulder,
Colorado
| – | -$1K | -17 | Closed |
|
XPH Hedge Fund Activity: Q2 2018 in Review
70 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2018, worth a combined $154M — down 15% from $182M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of XPH and 7 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 13 added.
The largest buyer was JGP Global Gestao de Recursos, opening a new position worth an estimated $6.3M. The largest seller was Bell Bank, exiting entirely with an estimated $18.1M sold.
- 70 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2018, down from 75 in Q1 2018.
- Funds reported $154M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2018, down 15% quarter-over-quarter.
- 7 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2018 and 12 closed out, a net change of -5 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2018 was JGP Global Gestao de Recursos, an estimated $6.3M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2018 was Bell Bank, an estimated $18.1M sold.
Based on aggregated 13F filings for Q2 2018.